Table 2 Prevalence of IgAD among SLE patients.
Year | Reference | Country | Age (years) | Sample size | IgAD (prevalence) | Criteria (g/L) |
|---|---|---|---|---|---|---|
1969 | 53 | USA | NM | 87 | 4 (1:22) | Undetectable |
1972 | 54 | Mexico | NM | 106 | 1 (1:106) | Traces |
1976 | 55 | USA | NM | 114 | 3 (1:38) | <0.10 |
1983 | 56 | UK | NM | 138 | 4 (1:35) | <0.05 |
1985 | 57 | Turkey | 9–66 | 96 | 3 (1:32) | <0.05 |
1988 | 58 | France | NM | 72 | 3 (1:24) | <0.10 |
1990 | 59 | Spain | NM | 130 | 1 (1:130) | <0.05 |
1991 | 60 | USA | NM | 75 | 3 (1:25) | NM |
1997 | 61 | UK | NM | 96 | 5 (1:19) | <0.5 |
2007 | 62 | USA | Children | 77 | 4 (1:19) | <0.01 |
| Â | Â | Â | Adults | 152 | 8 (1:19) | Absent |
2010 | 63 | Brazil | Adults | 189 | 11 (1:17) | <0.05 |
Total | Â | Â | Â | 1,332 | 50 (1:27) | Â |
Present study | ||||||
| Â | Â | Sweden | Adults | 706 | 11 (1:64) | <0.07 |
| Â | Â | UK | Adults | 844 | 5 (1:111) | <0.07 |
| Â | Â | USA | Adults | 874 | 20 (1:41) | <0.07 |
| Â | Â | China | Adults | 964 | 8 (1:121) | <0.07 |
Total | Â | Â | Â | 3,388 | 44 (1:77) | Â |